Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4417-4423

  Walter, Roland B ^a,b   Othus, Megan ^a,c   Borthakur, Gautam ^d   Ravandi, Farhad ^d   Cortes, Jorge E ^d   Pierce, Sherry A ^d   Appelbaum, Frederick R ^a,b   Kantarjian, Hagop A ^d   Estey, Elihu H ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RISK; TIME FACTORS;

EID: 81255175041     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.7525     Document Type: Article

References (24)

1. Altekruse SF, Kosary CL, Krapcho M, et al.: Childhood Cancer by the ICCC: SEER Cancer Statistics Review, 1975-2007. Bethesda, MD, National Cancer Institute, 2010. http://seer.cancer.gov/csr/1975-2007
2. Altekruse SF, Kosary CL, Krapcho M, et al.: Leukemia: SEER Cancer Statistics Review, 1975-2007. Bethesda, MD, National Cancer Institute, 2010. http://seer.cancer.gov/csr/1975-2007
3. Appelbaum FR, Gundacker H, Head DR, et al.: Age and acute myeloid leukemia. Blood 107:3481-3485, 2006
4. Estey E, Smith TL, Keating MJ, et al.: Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 3:257-263, 1989 (Pubitemid 19092757)
5. Giles FJ, Borthakur G, Ravandi F, et al.: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624-627, 2007 (Pubitemid 46148199)
6. Döhner H, Estey EH, Amadori S, et al.: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
7. Cheson BD, Bennett JM, Kopecky KJ, et al.: Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
8. Collett D: Modelling Survival Data in Medical Research (ed 2). Boca Raton, FL, Chapman and Hall/CRC, 2003
9. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996 (Pubitemid 26072233)
10. Harrell FE Jr, Margolis PA, Gove S, et al.: Development of a clinical prediction model for an ordinal outcome: The World Health Organization multicentre study of clinical signs and etiological agents of pneumonia, sepsis and meningitis in young infants WHO/ARI young infant multicentre study group. Stat Med 17:909-944, 1998 (Pubitemid 28185168)
11. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004 (Pubitemid 38380667)
12. Kantarjian H, Ravandi F, O'Brien S, et al.: Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116:4422-4429, 2010
13. Kantarjian H, O'Brien S, Cortes J, et al.: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 106:1090-1098, 2006
14. Malfuson JV, Etienne A, Turlure P, et al.: Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica 93:1806-1813, 2008
15. Wheatley K, Brookes CL, Howman AJ, et al.: Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 145:598-605, 2009
16. Krug U, Röllig C, Koschmieder A, et al.: Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet 376:2000-2008, 2010
17. Wheatley K, Burnett AK, Goldstone AH, et al.: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107:69-79, 1999 (Pubitemid 29500811)
18. Haferlach T, Kern W, Schoch C, et al.: A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica 89:408-418, 2004 (Pubitemid 38798545)
19. Elliott MA, Litzow MR, Letendre LL, et al.: Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 110:4172-4174, 2007 (Pubitemid 351377779)
20. Shook D, Coustan-Smith E, Ribeiro RC, et al.: Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma 9:S281-S285, 2009 (suppl 3)
21. Walter RB, Appelbaum FR, Tallman MS, et al.: Shortcomings in the clinical evaluation of new drugs: Acute myeloid leukemia as paradigm. Blood 116:2420-2428, 2010
22. Löwenberg B, Ossenkoppele GJ, van Putten W, et al.: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235-1248, 2009
23. Giles F, Vey N, DeAngelo D, et al.: Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood 114:4027-4033, 2009
24. Sorror ML: Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hematol Educ Program 2010:237-247, 2010